MOXONIDINE IN METABOLIC SYNDROME

Objective. Imidazoline receptor agonist moxonidine besides antihypertensive effect can increase insulin sensitivity, reduce leptin level, and improve lipid metabolism. However, the efficacy, tolerability and pleiotropic effects of moxonidine in postmenopausal women with essential hypertension (EH) and metabolic syndrome (MS) are not well established, and it was the purpose of this study.

 Design and methods. Forty-two postmenopausal women with EH and MS (mean age — 52,5 ± 0,4 years) were enrolled. Moxonidine therapy (400–600 mkg/ daily) lasted for 12 weeks. Waist (WC) and hip (HC) circumferences, WC/HC ratio, body mass index (BMI), insulin, leptin level, glucose, blood serum lipid profile, index of insulin resistance (HOMA-IR) and index of functional activity of pancreatic beta cells (HOMA-FB), echocardiography, intima-media thickness of common carotid arteries.

Results. Moxonidine therapy was associated with decrease, body weight and BMI decrease, high-density lipoprotein cholesterol and HOMA-FB index increase. Left atrium diameter and volume decreased, left ventricular diastolic function improved.

 Conclusions. Moxonidine is an effective antihypertensive drug for the treatment of postmenopausal hypertensive women with MS, which improves some metabolic, hemodynamic parameters and leads to the decrease of the left atrium volume and diameter.

1. Кириченко А.А. Лечение гипертонической болезни у женщин в постменопаузе // Практикующий врач. — 2003. — № 1. — С. 5–10. / Kirichenko A.A. Antihypertensive treatment in

2. postmenopausal women // Physician [Praktikuyushiy Vrach]. — 2003. — № 1. — Р. 5–10 [Russian].

3. De Michele M., Panico S., Iannuzzi A., et al. Association of obesity and central fat distribution with carotid artery wall thickening in middleaged women // Stroke. — 2002. — Vol. 33, № 12. — P. 2923–2928.

4. Haenni A., Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives // J. Hypertens. — 1999. — Vol. 17, Suppl. 3. — P. 29–35.

5. Sanjuliani A.F., Francischetti E.A., Genelhu de Abreu V. et al. Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin, and metabolic profile in obese hypertensive patients // J. Clin. Basic Cardiol. — 2004. — Vol. 7, № 1–4. — P. 19–25.

6. Sharma A.M., Wagner T., Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study // J. Hum. Hypertens. — 2004. — Vol. 18, № 9. — P. 669–675.

7. Chazova I.E., Almazov V.A., Shlyakhto E.V. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin (ALMAZ) // Diabetes Obes. Metab. — 2006. — Vol. 8. — P. 456–65.

8. Sattar N., Wannamethee G., Sarwar N. et al. Leptin and coronary heart disease, prospective study and systematic review // J. Am. Coll. Cardiol. — 2009. — Vol. 53, № 2. — P. 67–175.

9. Masajtis-Zagajewska A., Majer J., Nowicki M. Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients — a randomized, crossover trial // Hypertens. Res. — 2010. — Vol. 33, № 4. — Р. 348–353.

10. Benetos A., Safar M., Rudnichi A. et al. Pulse pressure. A predictor of long-term cardiovascular mortality in a french male population // Hypertension. — 1997. — Vol. 30, № 6. — P. 1410–1415.

11. Чазова И.Е., Мычка В.Б. Метаболический синдром, сахарный диабет 2 типа и артериальная гипертензия// Сердце. — 2003. — T. 2, № 3 (9). — С. 102–144. / Chazova I.E., Mychka V.B. Metabolic syndrome, type 2 diabetes mellitus and hypertension // Heart [Serdtse]. — 2003. — Vol. 2, № 3 (9). — Р. 102–144 [Russian].

12. Akasaka Y., Tsunoda M., Ide T. et al. Chronic leptin treatment stimulates lipid oxidation in immortalized and primary mouse skeletal muscle cells // Biochim. Biophys. Acta. — 2009. — Vol. 1791, № 2. — P. 103–109.

13. Aksnes T.A., Flaa A., Strand A., Kjeldsen S.E. Prevention of new-onset atrial fibrillation and its predictors with angiotensin IIreceptor blockers in the treatment of hypertension and heart failure // J. Hypertens. — 2007. — Vol. 25, № 1. — P. 15–23.

14. Mancia G., De Backer G.D., Dominiczak A. et al. Guidelines for the manangement of arterial hypertension // Eur. Heart J. — 2007. — Vol. 28, № 12. — P. 1462–1536.

15. Шиллер Н., Осипов М. А. Клиническая эхокардиография. — М.: Мир, 1993. – 347 с. / Schiller N., Osipov M.A. Clinical cardiac ultrasound. — Moscow: Mir, 1993. – 347 p. [Russian].

16. Schejbal V. Epicardial fatty tissue of the right ventricle morphology, morphometry and functional significance // Pneumologie. — 1989. — Vol. 43, № 9. — P. 490–499.

17. Wachtell K., Lehto M., Gerdts E. et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study // J. Am. Coll. Card. — 2005. — Vol. 45, № 5. — P. 712–719.

18. Schmieder R.E., Kjeldsen S.E., Julius S., Mclnnes G.T., ZanchettiA., Hua T.A. Reduced incidence of new-onset atrial fibrillation ith angiotensin II receptor blockade: the VALUE trial // J. Hypertens. — 2008. — Vol. 26, № 3. — P. 403–411.

19. Fogari R., Derosa G., Ferrari I. et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation // Am. J. Hypertens. — 2008. — Vol. 21, № 9. — P. 1034–1039.

20. Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013 // Pос. кардиол. журн. — 2014. — № 1 (105). / Guidelines on hypertension management. ESH/ESC 2013 // Russian Cardiology Journal [Rossiyskiy Kardiologicheskiy Zhurnal]. — 2014. — № 1 (105). — C. 5–92 [Russian].

21. Беляева О. Д., Березина А. В., Баженова Е. А., Чубенко Е.А., Баранова Е.И., Беркович О.А. Распространенность и варианты метаболического синдрома у пациентов с абдоминальным ожирением — жителей Санкт-Петербурга // Артериальная гипертензия. — 2012. — Т. 18, № 3. — C. 235–243. / Belyaeva O.D., Berezina A.V., Bazhenova E.A., Chubenko E.A., Baranova E.I., Berkovich O.A. Prevalence and forms of the metabolic syndrome in patients with abdominal obesity — in population of St Petersburg // Arterial Hypertension [Arterialnaya Gipertenziya].— 2012. — Vol. 18, № 3. — Р. 235–243 [Russian].

22. Подзолков В.И., Гладышева Е.А., Брагина А.Е. Роль моксонидина в комбинированной антигипертензивной терапии пациентов с метаболическим синдромом // Артериальная гипертензия. — 2007. — Т. 13, №4. — C. 246–249. / Podzolkov V.I., Gladysheva E.A., Bragina A.E. Moxonidin in combined therapy of metabolic syndrome // Arterial Hypertension [Arterialnaya Gipertenzya]. — 2007. — Vol. 13, № 4. — Р. 246–249 [Russian]